• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

byJessie WillisandTeddy Guo
October 12, 2022
in Chronic Disease, Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo.

2. Overall survival was significantly higher in nivolumab plus ipilimumab compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Melanoma is a form of skin cancer with the aggressive potential to metastasize to other organs of the body. This study assessed the use of immune checkpoint inhibitors in patients with previously resected stage IV melanoma and no current evidence of disease. Patients were randomly assigned to either a regimen of nivolumab plus ipilimumab, nivolumab alone, or placebo, for up to 1 year. Both the nivolumab-ipilimumab and nivolumab monotherapy groups showed significantly improved 4-year recurrence-free survival compared to placebo. Overall survival was additionally improved in the nivolumab plus ipilimumab group compared to placebo. Adverse events were consistent with previously described for the two drugs. Limitations of the IMMUNED trial include the study size. Nonetheless, the IMMUNED trial demonstrates the clinical benefit of nivolumab and ipilimumab in patients with stage IV melanoma with no evidence of disease.

Click to read the study in The Lancet

Relevant Reading: Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

RELATED REPORTS

Structured exercise intervention improves survival in colon cancer patients

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence

In-Depth [randomized controlled trial]: IMMUNED was a phase 2 drug trial that took place across 20 academic medical centres in Germany. Patients were eligible if they were aged 18-80 years and had previous stage IV cutaneous or unknown primary melanoma with no evidence of disease after radiotherapy or surgery. A total of 167 patients were randomized 1:1:1 to either nivolumab plus ipilimumab (n=56), nivolumab plus ipilimumab-matching placebo (n=59), or double placebo control (n=52). Treatment regimen was nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab 3 mg/kg every 2 weeks, nivolumab alone every 2 weeks, or matching placebo, for up to 1 year. The primary endpoint was recurrence-free survival. The median follow-up time was 49.2 months. The 4-year recurrence-free survival was highest in the nivolumab plus ipilimumab group (64.2%), followed by nivolumab alone (31.4%), and then placebo (15.0%). Compared to placebo, the hazard ratio for recurrence for the nivolumab plus ipilimumab group was 0.25 (97.5% CI 0.13-0.48, p<0.0001). For overall survival between nivolumab plus ipilimumab group versus placebo, the hazard ratio was 0.41 (p=0.04). There were no deaths related to the treatment. Grade 3-4 adverse events occurred in 71% of the nivolumab plus ipilimumab group compared to 29% of the nivolumab alone group.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced melanomacutaneous melanomadermatologyimmunotherapyipilimumabmelanomaNivolumaboncologyskin cancer
Previous Post

Collaborative home-based palliative care approach effective for heart failure patients

Next Post

Wellness Check: Exercise

RelatedReports

Development of a risk index for colorectal cancer screening
Gastroenterology

Structured exercise intervention improves survival in colon cancer patients

July 9, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025
Lessons from real-world implementation of lung cancer screening
Oncology

Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence

July 7, 2025
All Specialties

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

July 4, 2025
Next Post
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Wellness Check: Exercise

#VisualAbstract: Cefepime/enmetazobactam superior to piperacillin/tazobactam for the treatment of complicated urinary tract infections and acute pyelonephritis

#VisualAbstract: Cefepime/enmetazobactam superior to piperacillin/tazobactam for the treatment of complicated urinary tract infections and acute pyelonephritis

Glucocorticoid therapy may not be efficacious for pediatric COVID-19 without MIS-C

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage
  • #VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis
  • 2 Minute Medicine Rewind July 14, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.